Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 28 Nov 2025 17:05 CET |
NAVAMEDIC | Navamedic ASA: Resignation of CFO | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 Oct 2025 07:00 CET |
NAVAMEDIC | Navamedic ASA: Double digit growth in the 3rd quarter, 2025 | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 28 Oct 2025 07:00 CET |
NAVAMEDIC | Navamedic ASA: Tosifret vekst i tredje kvartal 2025 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 24 Oct 2025 17:56 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2025 3rd quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 17 Oct 2025 11:22 CEST |
NAVAMEDIC | Navamedic ASA: Navamedic extends its business into Germany together with Evolsin Medical | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 15 Oct 2025 13:46 CEST |
NAVAMEDIC | NOTIFICATION OF MAJOR HOLDINGS | 20103015 Pharmaceuticals | Major shareholding notifications |
| 14 Oct 2025 14:38 CEST |
NAVAMEDIC | Flaggemelding NAVA | 20103015 Pharmaceuticals | Major shareholding notifications |
| 13 Oct 2025 18:26 CEST |
NAVAMEDIC | Navamedic ASA - New share capital registered | 20103015 Pharmaceuticals | Total number of voting rights and capital |
| 07 Oct 2025 15:51 CEST |
NAVAMEDIC | Notification of major shareholding | 20103015 Pharmaceuticals | Major shareholding notifications |
| 07 Oct 2025 12:55 CEST |
NAVAMEDIC | Navamedic ASA: Allocation of shares in the rights issue to primary insiders and their close associates | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 07 Oct 2025 12:42 CEST |
NAVAMEDIC | Navamedic ASA: Final results of the rights issue | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 06 Oct 2025 20:47 CEST |
NAVAMEDIC | Navamedic ASA: Preliminary results of the rights issue | 20103015 Pharmaceuticals | Inside information |
| 06 Oct 2025 16:49 CEST |
NAVAMEDIC | Flaggemelding | 20103015 Pharmaceuticals | Flagging |
| 06 Oct 2025 08:00 CEST |
NAVAMEDIC | Navamedic ASA: Last day of the subscription period in the rights issue | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 03 Oct 2025 19:49 CEST |
NAVAMEDIC | Navamedic ASA: Mandatory notification of trades by primary insiders and their close associates | 20103015 Pharmaceuticals | Meldepliktig handel for primærinnsidere |
| 30 Sep 2025 08:00 CEST |
Navamedic ASA | Navamedic ASA: Last day of trading in subscription rights | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 Sep 2025 21:26 CEST |
NAVAMEDIC | Navamedic ASA: Receipt of subscription rights in the rights issue by primary insiders and their close associates | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 22 Sep 2025 07:30 CEST |
NAVAMEDIC | Navamedic ASA: Commencement of the subscription period for the rights issue | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Sep 2025 11:05 CEST |
NAVAMEDIC | Navamedic ASA: Approval and publication of prospectus | 20103015 Pharmaceuticals | Prospectus / admission document |
| 01 Sep 2025 12:45 CEST |
NAVAMEDIC | Navamedic ASA: Updated key information relating to the rights issue | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 Aug 2025 15:19 CEST |
NAVAMEDIC | Flaggemelding | 20103015 Pharmaceuticals | Flagging |
| 14 Aug 2025 07:00 CEST |
NAVAMEDIC | Navamedic ASA: Rapport for 2. kvartal og første halvår 2025 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 14 Aug 2025 07:00 CEST |
NAVAMEDIC | Navamedic ASA: Financial report for the 2nd quarter and first half of 2025 | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 13 Aug 2025 09:51 CEST |
NAVAMEDIC | Navamedic ASA: National approvals of Flexilev® in OraFID® granted across all Nordic countries. | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 11 Aug 2025 13:03 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2025 2nd quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 15 Jul 2025 12:32 CEST |
NAVAMEDIC | Navamedic ASA: Closing of the transaction to acquire the business of dne pharma | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 15 Jul 2025 08:25 CEST |
NAVAMEDIC | Navamedic ASA: Ex. subscription rights today | 20103015 Pharmaceuticals | Ex Date |
| 14 Jul 2025 15:27 CEST |
NAVAMEDIC | Navamedic ASA - Minutes of Extraordinary General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 11 Jul 2025 14:16 CEST |
NAVAMEDIC | Navamedic ASA: Mandatory notice of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 10 Jul 2025 10:49 CEST |
NAVAMEDIC | Navamedic ASA: Updated key information relating to the rights issue | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 29 Jun 2025 13:36 CEST |
NAVAMEDIC | Navamedic ASA - Additional underwriting commitments in the Rights Issue | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Jun 2025 14:14 CEST |
NAVAMEDIC | Navamedic ASA: First approval of the medical device OraFID® as primary package for a pharmaceutical product | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 24 Jun 2025 08:00 CEST |
NAVAMEDIC | Navamedic ASA - Investor presentation regarding the acquisition of the business of dne pharma AS | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 23 Jun 2025 17:35 CEST |
NAVAMEDIC | Navamedic ASA: Mandatory notice of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 23 Jun 2025 12:45 CEST |
NAVAMEDIC | Navamedic ASA: Notice of extraordinary general meeting on 14 July 2025 in connection with a contemplated rights issue | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Jun 2025 08:15 CEST |
NAVAMEDIC | Navamedic ASA: Key information relating to the Rights Issue | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Jun 2025 08:00 CEST |
NAVAMEDIC | Navamedic ASA expands into addiction treatment through the acquisition of the business of dne pharma and announces a partially underwritten rights issue | 20103015 Pharmaceuticals | Inside information |
| 04 Jun 2025 10:29 CEST |
NAVAMEDIC | Navamedic ASA: Minutes of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 14 May 2025 14:35 CEST |
NAVAMEDIC | Navamedic ASA: Notice of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 05 May 2025 10:56 CEST |
NAVAMEDIC | Navamedic ASA launches Eroxon® in Denmark | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 30 Apr 2025 19:42 CEST |
NAVAMEDIC | Navamedic ASA: Annual Report 2024 | 20103015 Pharmaceuticals | Annual financial and audit Reports |
| 30 Apr 2025 07:00 CEST |
NAVAMEDIC | Navamedic Q1 2025: Strong start of the year and well-positioned for future growth | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 30 Apr 2025 07:00 CEST |
NAVAMEDIC | Navamedic Q1 2025: Sterk start på året og godt posisjonert for fremtidig vekst | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 29 Apr 2025 17:35 CEST |
NAVAMEDIC | Navamedic ASA: Imdur® distribution agreement extended to 2032 | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 28 Apr 2025 16:44 CEST |
NAVAMEDIC | Navamedic ASA: Conclusion received from the Norwegian Financial Supervisory Authority | 20103015 Pharmaceuticals | Inside information |
| 28 Apr 2025 12:06 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2025 1st quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 10 Apr 2025 08:50 CEST |
NAVAMEDIC | Navamedic ASA: Navamedic has entered into an agreement in principle with Observe Medical ASA to reduce the loan receivable by 50% | 20103015 Pharmaceuticals | Inside information |
| 01 Apr 2025 15:00 CEST |
NAVAMEDIC | Navamedic Welcomes CHMP's Positive Review of Mysimba's Cardiovascular Safety | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 28 Mar 2025 14:25 CET |
NAVAMEDIC | Navamedic ASA: Letter received from the Norwegian Financial Supervisory Authority | 20103015 Pharmaceuticals | Inside information |
| 19 Mar 2025 15:52 CET |
NAVAMEDIC | Navamedic ASA: Mandatory notice of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |